Exelixis, Inc. (EXEL) Stock Price & How to Invest

Exelixis, Inc. is a commercial-stage oncology company whose business is dominated by cabozantinib, sold in the United States as CABOMETYX. Cabozantinib is a tyrosine kinase inhibitor (TKI) approved across several cancers, most importantly advanced renal cell carcinoma (kidney cancer) and certain neuroendocrine tumors, and it is the market-leading TKI in second-line-plus kidney cancer. In the first quarter of 2026, cabozantinib captured roughly 47% of total TKI prescriptions in its core setting, up from about 44% a year earlier, and the franchise generated the large majority of company revenue. Unlike clinical-stage biotechs that burn cash, Exelixis is solidly profitable and returns capital through share buybacks.

The investment picture in mid-2026 balances a growing, cash-generating core drug against a looming patent cliff and a high-stakes pipeline transition. Cabozantinib faces generic competition risk later this decade (litigation has pushed the timeline out, with meaningful generic exposure viewed as a post-2029 event), so the company is racing to launch its successor molecule, zanzalintinib, in new indications. The pivotal STELLAR-303 trial in previously treated metastatic colorectal cancer met its primary overall-survival endpoint, and an NDA for zanzalintinib plus atezolizumab was accepted for U.S. review, with a regulatory decision expected around December 2026. Exelixis is expanding its gastrointestinal sales team ahead of a potential colorectal launch, making 2026 a bridge year between the mature cabozantinib franchise and the zanzalintinib era.

The dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. Cabozantinib faces a patent cliff and generic competition risk later this decade (litigation has delayed but not removed it), which makes the zanzalintinib transition critical and time-sensitive. Pipeline risk is real, as trials can miss endpoints or draw a narrow label, and Exelixis has already discontinued some zanzalintinib programs such as head and neck cancer. Regulatory timing, including the roughly December 2026 colorectal decision, can slip. Competition in kidney and colorectal cancer from large pharma and other TKIs and immunotherapies is intense, and the stock can move sharply on binary clinical and regulatory news.

15 analysts publish price targets on EXEL, averaging $52.07 against a $53.03 price as of August 2026, or -1.8%. The published targets run from $41.00 to $64.00, a moderate spread, and the ratings split 8 buy, 10 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EXEL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Exelixis, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Cabozantinib franchise growth. Cabozantinib remains the growth engine, with Q1 2026 cabozantinib franchise net product revenue of about $555 million and continued share gains as the leading TKI in second-line-plus kidney cancer and the oral market leader in neuroendocrine tumors. The most optimistic published target, $64.00, assumes this works close to its best case.

The case against. The dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. The most pessimistic target, $41.00, is roughly what EXEL is worth if this bites instead.

Read the full bull and bear case on EXEL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Exelixis, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.2 billion (Q1 2026 total revenue was ~$611 million, up ~10% year over year)
• 2026 revenue guidance: ~$2.525 to $2.625 billion total (net product ~$2.325 to $2.425 billion)
• Non-GAAP net income (Q1 2026): ~$233 million (~$0.87 diluted per share, beating estimates)
• Cash and marketable securities: ~$1.65 billion, with a new ~$750 million buyback authorized
• Market cap: ~$13 to $14 billion (stock in the mid-$50s per share)
• P/E ratio: ~18x trailing, ~15x forward

Figures are approximate and tied to the asOf date, so verify live numbers before acting. Exelixis trades at a moderate biotech multiple that partly reflects its rare profitability, but that multiple embeds two big assumptions: that cabozantinib keeps growing into the patent cliff and that zanzalintinib successfully replaces it. Because so much value hinges on clinical and regulatory outcomes, the valuation is more sensitive to STELLAR trial data and the colorectal decision than to any single earnings print.

If you want EXEL exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to EXEL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EXEL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT, XMHQ), which spreads the position across many companies. Or build it into a focused thematic portfolio, so EXEL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EXEL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Exelixis is a rare cash-generative biotech carried by a single dominant cancer drug, so the picture turns on cabozantinib durability plus zanzalintinib pipeline execution rather than on any one quarter, and how much single-drug concentration risk you are comfortable holding.

Whether EXEL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EXEL a buy or a sell?, and where the stock could go from here in the EXEL stock forecast.

For income investors, whether EXEL pays a dividend and how the payout looks is covered in does EXEL pay a dividend? And to weigh EXEL against a peer, read the full side-by-side comparisons: EXEL vs PFE and EXEL vs BMY.